Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for SurvivalŁukasz Biegała, Aneta Rogalska|Cells|2023Cited by 23
Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell LinesPatrycja Gralewska, Aneta Rogalska|International Journal of Molecular Sciences|2025Cited by 5
MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX ModelWiktoria Bębenek, Aneta Rogalska|International Journal of Molecular Sciences|2025Cited by 1
Liposomal Vitamin C as a Modulator of the Efficacy of Ceralasertib Therapy in Ovarian CancerPatrycja Gralewska-Zając, Aneta Rogalska|International Journal of Molecular Sciences|2026Cited by 0